Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD
Release Date: 06/04/2025
A deep dive into iPledge changes with John Barbieri, MD
Beneath the Surface
In this episode, guest John Barbieri, MD, MBA, discusses the FDA’s 2023 proposed changes to the iPledge system and the impacts of clinical trials and treatments on patients with hormonal acne. • Intro 0:28 • John Barbieri, MD, MBA 0:42 • What does it mean to have a conditional recommendation, and why is this considered “controversial”? 1:50 • What are the reasons, such as limitations of use, that lead to a conditional recommendation? 2:48 • How would you implement these care guidelines into clinical...
info_outline
The science behind vitiligo with John Harris, MD, PhD
Beneath the Surface
In this episode, guest John E. Harris, MD, PhD, discusses how vitiligo occurs and how dermatologists can navigate the vitiligo treatment landscape. • Intro 0:28 • John E. Harris, MD, PhD 0:41 • How does vitiligo occur, and what is the basic science behind it? 1:08 • Are there any known triggers of this condition in people who have genetic susceptibility to it? 3:19 • How does drug-induced vitiligo occur in people? 4:42 • When you see a patient with vitiligo, how do you approach the...
info_outline
Exploring sodium’s effect on dermatologic disease with Katrina Abuabara, MD
Beneath the Surface
In this episode, guest Katrina Abuabara, MD, discusses the possible role of sodium in dermatologic diseases and how dermatologists can make recommendations for patients’ sodium intake. • Intro 0:29 • Katrina Abuabara, MD, MA, MSCE 0:41 • What made you think about the question behind your paper on ? 1:08 • How do you measure sodium in the skin? 2:49 • In which dermatologic diseases are abnormal sodium in the skin playing a significant role? 3:36 • Is there any evidence that changing...
info_outline
Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD
Beneath the Surface
In this episode, guest Brett King, MD, PhD, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata and conversations with patients surrounding medical pauses. • Intro 0:29 • Brett King, MD, PhD 0:41 • When a patient comes to the office with alopecia areata and want to go on a JAK inhibitor, how do you counsel them about their likelihood for significant hair regrowth? 1:35 • Is your estimate of roughly fifty percent rate from data, or from your own experiences with patients? 6:03 •...
info_outline
How to embrace AI responsibly with Roxana Daneshjou, MD, PhD
Beneath the Surface
In this episode, guest Roxana Daneshjou, MD, PhD, discusses the role of artificial intelligence in dermatology practice, and the future of AI models in medicine. • Intro 0:29 • Roxana Daneshjou, MD, PhD 0:45 • What is artificial intelligence? 1:10 • What led to this largely academic endeavor becoming deployable? 2:36 • How is AI being deployed in health care today? 5:36 • What is currently deployable about AI in the dermatology space? 7:56 • How long do you think it will be...
info_outlineIn this episode, guest Brett King, MD, PhD, discusses the efficacy of Janus kinase (JAK) inhibitors for the treatment of alopecia areata and conversations with patients surrounding medical pauses.
• Intro 0:29
• Brett King, MD, PhD 0:41
• When a patient comes to the office with alopecia areata and want to go on a JAK inhibitor, how do you counsel them about their likelihood for significant hair regrowth? 1:35
• Is your estimate of roughly fifty percent rate from data, or from your own experiences with patients? 6:03
• How do you explain boxed warnings to patients using or thinking about using JAK inhibitors? 8:29
• Gelfand and King on the challenges presented by the current data on alopecia areata patients using JAK inhibitors. 12:02
• Is it true that patients experience hair loss quickly after going off JAK inhibitors? 12:49
• How do you manage these challenges in real-world clinical practice? 13:40
• With JAK, how do you deal with the issue of non-follow-up patients? 17:42
• Thank you, Dr. King. 19:55
Brett King, MD, PhD, is an associate professor of dermatology at Yale School of Medicine.
We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn. King can be reached on X @Brett_King_ and on LinkedIn.
For more, be sure to visit the Beneath the Surface video blog on Healio.com.
Disclosures: Gelfand reports no relevant financial disclosures. King reports having financial relationships with AbbVie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Arena Pharmaceuticals, Aslan Pharmaceuticals, BiologicsMD, Bristol Meyers Squibb, Concert Pharmaceuticals, Eli Lilly, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka/Visterra, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, TWi Biotechnology and Ventyx Biosciences.